

OSUCCC Intramural Research Program
List of eligible awards to apply for
Supplements to Promote Diversity in Cancer Research

Original IRP Number	IRP Cycle	PIs	Title
IRP00732	FA2019	Garzon/Phelps	Development of LNA gapmers anti-HOXB-AS3 to treat Acute Myeloid Leukemia
IRP00794	FA2019	Muthusamy/Yu	Strategic elimination of leukemic B cells while sparing normal B cells in Chronic Lymphocytic Leukemia
IRP00780	FA2019	Kirschner	Development of BioID Techniques for Identification of Protein Interactomes in vivo
IRP00746	FA2019	Roychowdhury	Liquid Biopsy for Rapid Detection and Real Time Monitoring for FGFR-altered cancers
IRP00801	FA2019	He/Kneuert/Lozanski/Oezkan	Single-cell analysis of T cell subsets infiltrating into tumor and in metastatic and uninvolved lymph nodes of small cell lung cancer patients
IRP00784	FA2019	S Sizemore	PPP2R1B in dedifferentiated liposarcoma
IRP00803	FA2019	Wagener/Brinkman	The Impact of E-cigarette Liquid Nicotine Form on Puffing Behavior, Abuse Liability and Cancer Risk
IRP00825	SP2020	Reneau	A pilot phase I trial of IL-21 expanded, off the shelf, third-party natural killer (NK) cells in combination with mogamulizumab in patients with Cutaneous T-Cell Lymphomas or Adult T-cell Leukemia/Lymphomas
IRP00835	SP2020	Jacob	Senolytic Agents as Mitigators of Delayed Radiation Toxicities
IRP00841	SP2020	Owen	A phase 1b dose de-escalation study of atezolizumab and all-trans retinoic acid in patients with advanced non-small cell lung cancer
IRP00852	SP2020	Miller	Early Detection of Cardiotoxicity After Lower Thoracic Radiotherapy
IRP00818	SP2020	Toland	Zebrafish models to characterize OCA2 skin cancer risk variants
IRP00836	SP2020	Cruz-Monserrate	Adipose Tissue Contributions to Pancreatic Cancer Development
IRP00815	SP2020	Brasky	A trial of long-chain omega-3 fatty acids in a murine model of complex atypical endometrial hyperplasia
IRP00923	FA2020	Alinari	Targeting c-Myc stability in c-Myc driven Diffuse Large B-cell Lymphoma
IRP00926	FA2020	Ganju	S100A9 as a novel therapeutic target against small cell lung cancer
IRP00936	FA2020	Memmott	A phase 1b study of osimertinib and tegavivint as first-line therapy in patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC)
IRP00948	FA2020	Ejaz	Effect of TIVA on circulating biomarkers and clinical outcomes following pancreatic cancer surgery
IRP00908	FA2020	Skardal	Ex vivo generation of tumor-reactive T cells using an immune enhanced, patient derived tumor organoid-on-a-chip (iTOC)
IRP00927	FA2020	Arthur	Vaginal microbiome as a biomarker of pelvic health and patient-reported outcomes in women receiving pelvic radiation
IRP00904	FA2020	Cocucci	A new mouse model to assess rigor and reproducibility of extracellular vesicles as cancer biomarkers

IRP00915	FA2020	Hu	Enhancing immune checkpoint blockade therapy for treatment of triple-negative breast cancer
IRP00940	FA2020	Rosko	Moving Mountains: increasing myeloma transplant access for vulnerable patient populations and appalachia
IRP00969	SP2021	Mims/Eisfeld	Identification of molecular treatment response predictors and associated genomic response patterns in AML patients with IDH mutations
IRP00980	SP2021	Zhang	Targeting CD40 for cancer therapy beyond an immune response
IRP00976	SP2021	Sparreboom	Cardiac OCT3 biomarker identification and validation
IRP00992	SP2021	Coppola	Establishing the importance of the CTLH complex in NSCLC
IRP00960	SP2021	Wen/He	Targeting immune inhibitory molecule SUSD2 to rejuvenate CD8+ T cell antitumor immunity
IRP00979	SP2021	Alinari	CD74 CAR-T cell therapy in mantle cell lymphoma
IRP01000	SP2021	Contreras	Project Limb Rescue: A pilot study evaluating the feasibility of transcutaneous sensors for the detection of cancer-related lymphedema
IRP00986	SP2021	Obeng-Gyasi/Andersen/Rahurkar/Stover	Development of a risk assessment tool to identify triple negative breast cancer patients at risk of rapid relapse
IRP00982	SP2021	Song/Shields	The pulmonary effects of a standardized research electronic cigarettes: protonated nicotine effects
IRP00983	SP2021	Bhat	Phase II comparative study of anti-pneumococcal vaccine strategy in patients with chronic lymphocytic leukemia